Evaluating the Symbicort Turbuhaler (Formoterol/Budesonide) Maintenance and Reliever Therapy for Asthma in Daily Practice

AstraZeneca

Status: Completed

Conditions: Asthma

Study type: Observational

Funder types: Industry

Identifiers

NCT00782314

NIS-RSI-SYM-2008/1

Details and patient eligibility

About

We want to evaluate efficacy of Symbicort® Turbuhaler® (formoterol/budesonide) therapy for asthma in real life conditions. For this purpose we will include both patients that are treated with Symbicort® Turbuhaler® the "classical" maintenance only treatment approach as well as those treated with the SMART approach.

Enrollment: 400 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients diagnosed with persistent asthma treated with Symbicort® Turbuhaler® in line with its label
• non-pregnant females
• existing maintenance only treatment with Symbicort® Turbuhaler® 80 μg/4,5 μg, 160 μg/4,5 μg or 320 μg/9 μg for at least 1 month
• existing SMART treatment with Symbicort® Turbuhaler® 80 μg/4,5 μg or 160 μg /4,5 μg for at least 1 month

Exclusion criteria

• patients not being treated with Symbicort® Turbuhaler®
• patients treated with Symbicort® Turbuhaler® for COPD

Trial design

400 participants in 2 patient groups

1

Description:

patients with maintenance only treatment with Symbicort Turbuhaler for at least 1 month

2

Description:

patients with SMART treatment with Symbicort Turbuhaler for at least 1 month